AR050537A1 - Produccion de proteina de fusion tnfr-ig - Google Patents
Produccion de proteina de fusion tnfr-igInfo
- Publication number
- AR050537A1 AR050537A1 ARP050103596A ARP050103596A AR050537A1 AR 050537 A1 AR050537 A1 AR 050537A1 AR P050103596 A ARP050103596 A AR P050103596A AR P050103596 A ARP050103596 A AR P050103596A AR 050537 A1 AR050537 A1 AR 050537A1
- Authority
- AR
- Argentina
- Prior art keywords
- culture
- accumulated
- tnfr
- glutamine
- conditions
- Prior art date
Links
- 230000014616 translation Effects 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 4
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 238000004113 cell culture Methods 0.000 abstract 3
- 230000007423 decrease Effects 0.000 abstract 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 2
- 229960001230 asparagine Drugs 0.000 abstract 2
- 235000009582 asparagine Nutrition 0.000 abstract 2
- 230000001186 cumulative effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000003698 anagen phase Effects 0.000 abstract 1
- 238000012136 culture method Methods 0.000 abstract 1
- 229910001410 inorganic ion Inorganic materials 0.000 abstract 1
- 238000012007 large scale cell culture Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El uso de dicho sistema permite altos niveles de produccion de proteínas y disminuye la acumulacion de ciertos factores indeseables, tales como amonio y lactato. Adicionalmente se proveen métodos de cultivo que incluyen un cambio de temperatura, que habitualmente comprende una disminucion en la temperatura cuando el cultivo ha alcanzado alrededor de 20%-80% de su densidad celular máxima. Además, se proveen métodos tales que después de alcanzar un pico, los niveles de lactato y amonio en el cultivo disminuyen con el transcurso del tiempo. Reivindicacion 1: Un método para la produccion de TNFR-Ig en un cultivo celular de produccion de gran escala, que comprende las etapas de: la provision de un cultivo celular que comprende: células de mamíferos que contienen un gen que codifica TNFR-Ig, donde dicho gen se expresa en condiciones de cultivo celular; y un medio que contiene glutamina, y que tiene una característica del medio seleccionada del grupo que consiste en: a) una cantidad acumulada de aminoácidos por unidad de volumen mayor que aproximadamente 70 mM; b) una relacion molar de glutamina acumulada a asparagina acumulada inferior a aproximadamente 2; c) una relacion molar de glutamina acumulada a aminoácidos totales acumulados inferior a aproximadamente 0,2; d) una relacion molar de ion inorgánico acumulado a aminoácidos totales acumulados de entre alrededor de 0,4 y 1; e) una cantidad acumulada combinada de glutamina y asparagina por unidad de volumen, superior a aproximadamente 16 mM; y sus combinaciones; el mantenimiento de dicho cultivo en una fase de crecimiento inicial, en un primer conjunto de condiciones de cultivo, durante un primer período suficiente para permitir que dichas células se reproduzcan hasta una densidad celular viable dentro de un rango de aproximadamente 20%-80% de la densidad celular viable posible máxima si dicho cultivo se mantuviera en el primer conjunto de condiciones de cultivo; el cambio de por lo menos una de las condiciones de cultivo, de manera de aplicar un segundo conjunto de condiciones de cultivo; el mantenimiento de dicho cultivo durante un segundo período, en el segundo conjunto de condiciones y durante un segundo período, de manera de acumular TNFR-Ig en el cultivo celular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60537904P | 2004-08-27 | 2004-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050537A1 true AR050537A1 (es) | 2006-11-01 |
Family
ID=35500648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103596A AR050537A1 (es) | 2004-08-27 | 2005-08-26 | Produccion de proteina de fusion tnfr-ig |
| ARP120104234A AR088824A2 (es) | 2004-08-27 | 2012-11-09 | Metodo para la produccion de tnfr-ig (receptor de factor de necrosis tumoral-inmunoglobulina) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104234A AR088824A2 (es) | 2004-08-27 | 2012-11-09 | Metodo para la produccion de tnfr-ig (receptor de factor de necrosis tumoral-inmunoglobulina) |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US7300773B2 (es) |
| EP (2) | EP1992697B1 (es) |
| JP (3) | JP2008511330A (es) |
| KR (1) | KR100988451B1 (es) |
| CN (2) | CN102876761A (es) |
| AR (2) | AR050537A1 (es) |
| AT (2) | ATE446376T1 (es) |
| AU (1) | AU2005280036B2 (es) |
| BR (1) | BRPI0514694B8 (es) |
| CA (1) | CA2578138C (es) |
| CL (1) | CL2017000577A1 (es) |
| CR (2) | CR8998A (es) |
| CY (2) | CY1109721T1 (es) |
| DE (2) | DE602005020076D1 (es) |
| DK (2) | DK1781802T3 (es) |
| EC (1) | ECSP077354A (es) |
| EG (1) | EG26922A (es) |
| ES (2) | ES2335518T3 (es) |
| GT (2) | GT200500234A (es) |
| HN (1) | HN2005000485A (es) |
| HR (2) | HRP20100011T1 (es) |
| IL (1) | IL181588A (es) |
| MX (1) | MX2007002381A (es) |
| MY (1) | MY137803A (es) |
| NO (1) | NO344785B1 (es) |
| NZ (1) | NZ579208A (es) |
| PE (2) | PE20060815A1 (es) |
| PL (2) | PL1992697T3 (es) |
| PT (2) | PT1781802E (es) |
| RS (2) | RS51255B (es) |
| RU (1) | RU2458988C2 (es) |
| SI (2) | SI1781802T1 (es) |
| SV (1) | SV2006002211A (es) |
| TW (1) | TWI364458B (es) |
| UA (1) | UA89383C2 (es) |
| WO (1) | WO2006026447A2 (es) |
| ZA (1) | ZA200701672B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
| RU2463345C2 (ru) * | 2006-07-13 | 2012-10-10 | Вайет | Получение гликопротеинов |
| JP5401319B2 (ja) * | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | 細胞培養における解糖阻害物質 |
| RU2520810C2 (ru) * | 2006-11-08 | 2014-06-27 | Вайет | Рационально разработанные среды для культивирования клеток |
| KR20090127326A (ko) | 2007-03-02 | 2009-12-10 | 와이어쓰 | 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도 |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| JP5576115B2 (ja) | 2007-04-26 | 2014-08-20 | 中外製薬株式会社 | 高濃度アミノ酸含有培地を用いた細胞の培養方法 |
| US8039231B2 (en) * | 2008-04-17 | 2011-10-18 | Wyeth Llc | Methods for enhanced production of bone morphogenetic proteins |
| WO2009127098A1 (zh) * | 2008-04-18 | 2009-10-22 | 上海中信国健药业有限公司 | 一种浓缩培养液及其使用方法 |
| WO2010016943A2 (en) * | 2008-08-08 | 2010-02-11 | Biogen Idec Ma Inc. | Nutrient monitoring and feedback control for increased bioproduct production |
| KR20180010324A (ko) | 2009-08-11 | 2018-01-30 | 제넨테크, 인크. | 글루타민-비함유 세포 배양 배지에서의 단백질의 생성 |
| WO2011068993A1 (en) * | 2009-12-02 | 2011-06-09 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins. |
| EP3862423A1 (en) | 2010-04-26 | 2021-08-11 | Novartis AG | Improved cell cultivation process |
| AU2011246504B2 (en) | 2010-04-26 | 2013-09-26 | Novartis Ag | Improved cell culture medium |
| JP2013535981A (ja) | 2010-08-20 | 2013-09-19 | ワイス・エルエルシー | 成長因子不含適合細胞の細胞培養 |
| AU2011329053A1 (en) * | 2010-11-15 | 2013-06-06 | Biogen Inc. | Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography |
| RU2580020C2 (ru) | 2011-04-29 | 2016-04-10 | Биокон Рисерч Лимитед | Способ снижения гетерогенности антител и способ получения соответствующих антител |
| EP2718328A4 (en) | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| TWI595883B (zh) | 2011-10-18 | 2017-08-21 | 柯赫勒斯生物科學有限公司 | 用木糖醇穩定化之依那西普調配物 |
| JP6400473B2 (ja) | 2011-10-21 | 2018-10-03 | ファイザー・インク | 細胞培養を改善するための鉄の添加 |
| KR20140135766A (ko) * | 2012-02-22 | 2014-11-26 | 엔브이아이피 피티와이 리미티드 | 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법 |
| WO2014011672A1 (en) | 2012-07-09 | 2014-01-16 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| BR112015005161A2 (pt) | 2012-09-11 | 2017-07-04 | Coherus Biosciences Inc | etanercepte corretamente dobrado em alta pureza e excelente rendimento |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| SG11201507875RA (en) | 2013-03-26 | 2015-10-29 | Coherus Biosciences Inc | Protein production method |
| KR101439195B1 (ko) | 2013-04-18 | 2014-09-12 | 동아대학교 산학협력단 | 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정 |
| US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| DK3055409T3 (en) * | 2013-10-11 | 2018-07-30 | Regeneron Pharma | METABOLIC OPTIMIZED CELL CULTURE |
| US10047141B2 (en) | 2014-01-30 | 2018-08-14 | Coherus Biosciences, Inc. | Method of manufacturing a protein by perfusion in media with a low amino acid concentration |
| WO2015120056A1 (en) | 2014-02-04 | 2015-08-13 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| PL3227454T3 (pl) * | 2014-12-01 | 2020-07-27 | Amgen Inc. | Sposób manipulowania poziomem zawartości glikanów w glikoproteinie |
| KR102007930B1 (ko) | 2014-12-31 | 2019-08-06 | 주식회사 엘지화학 | 재조합 당단백질의 글리코실화 조절 방법 |
| CN105777897A (zh) * | 2015-03-20 | 2016-07-20 | 广东东阳光药业有限公司 | 一种cho细胞收获液的前处理方法 |
| CN114807010B (zh) * | 2015-04-01 | 2024-11-29 | 勃林格殷格翰国际公司 | 细胞培养基 |
| KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
| KR102446838B1 (ko) | 2016-10-21 | 2022-09-26 | 암젠 인크 | 약학적 제형 및 그의 제조 방법 |
| GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| CN110484487A (zh) * | 2019-08-21 | 2019-11-22 | 安徽欣乐生物技术有限公司 | 一种适用于cho细胞培养用无蛋白培养基及其培养方法 |
| US12516103B2 (en) | 2020-12-22 | 2026-01-06 | Amgen Inc. | Cell culture method |
| CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
| CN114480492B (zh) * | 2022-01-28 | 2023-04-21 | 景泽生物医药(合肥)股份有限公司 | 一种重组人抗体融合蛋白的制备方法 |
| CN119510778A (zh) * | 2024-12-31 | 2025-02-25 | 北京同立海源生物科技有限公司 | 一种高稳定性的pdgf-bb活性检测方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5672502A (en) * | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1990003430A1 (en) * | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US6291159B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| EP0494955B1 (en) * | 1989-10-05 | 1998-07-15 | Optein, Inc. | Cell-free synthesis and isolation of novel genes and polypeptides |
| US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5538983A (en) * | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| US5156964A (en) * | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
| US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
| GB9118664D0 (en) * | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
| US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片 |
| US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
| US5856179A (en) * | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| JP4306813B2 (ja) * | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| US20020012991A1 (en) * | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| WO2000023082A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| AU2002258808A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
| WO2002088307A2 (en) | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
| US20030087372A1 (en) | 2001-06-13 | 2003-05-08 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| AU2003217612A1 (en) | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
| WO2003072714A2 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| HUE030806T2 (hu) | 2002-05-02 | 2017-05-29 | Wyeth Holdings Llc | Calicheamicin származék-hordozó konjugátumok |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
-
2005
- 2005-08-25 TW TW094129077A patent/TWI364458B/zh not_active IP Right Cessation
- 2005-08-25 US US11/213,633 patent/US7300773B2/en not_active Expired - Lifetime
- 2005-08-26 HR HR20100011T patent/HRP20100011T1/hr unknown
- 2005-08-26 DK DK05791482.2T patent/DK1781802T3/da active
- 2005-08-26 DE DE602005020076T patent/DE602005020076D1/de not_active Expired - Lifetime
- 2005-08-26 CN CN2012102771283A patent/CN102876761A/zh active Pending
- 2005-08-26 UA UAA200703287A patent/UA89383C2/ru unknown
- 2005-08-26 EP EP08005732A patent/EP1992697B1/en not_active Revoked
- 2005-08-26 DE DE602005017285T patent/DE602005017285D1/de not_active Expired - Lifetime
- 2005-08-26 BR BRPI0514694A patent/BRPI0514694B8/pt active IP Right Grant
- 2005-08-26 PL PL08005732T patent/PL1992697T3/pl unknown
- 2005-08-26 CN CN2005800369388A patent/CN101061231B/zh not_active Expired - Fee Related
- 2005-08-26 ES ES05791482T patent/ES2335518T3/es not_active Expired - Lifetime
- 2005-08-26 WO PCT/US2005/030439 patent/WO2006026447A2/en not_active Ceased
- 2005-08-26 DK DK08005732.6T patent/DK1992697T3/da active
- 2005-08-26 MY MYPI20054023A patent/MY137803A/en unknown
- 2005-08-26 PL PL05791482T patent/PL1781802T3/pl unknown
- 2005-08-26 HN HN2005000485A patent/HN2005000485A/es unknown
- 2005-08-26 GT GT200500234A patent/GT200500234A/es unknown
- 2005-08-26 GT GT200500233A patent/GT200500233A/es unknown
- 2005-08-26 SI SI200530874T patent/SI1781802T1/sl unknown
- 2005-08-26 RS RSP-2010/0190A patent/RS51255B/sr unknown
- 2005-08-26 SV SV2005002211A patent/SV2006002211A/es unknown
- 2005-08-26 PE PE2005000987A patent/PE20060815A1/es not_active Application Discontinuation
- 2005-08-26 SI SI200530984T patent/SI1992697T1/sl unknown
- 2005-08-26 MX MX2007002381A patent/MX2007002381A/es active IP Right Grant
- 2005-08-26 AT AT05791482T patent/ATE446376T1/de active
- 2005-08-26 AR ARP050103596A patent/AR050537A1/es not_active Application Discontinuation
- 2005-08-26 JP JP2007530167A patent/JP2008511330A/ja active Pending
- 2005-08-26 RS RSP-2009/0575A patent/RS51072B/sr unknown
- 2005-08-26 ES ES08005732T patent/ES2341390T3/es not_active Expired - Lifetime
- 2005-08-26 PT PT05791482T patent/PT1781802E/pt unknown
- 2005-08-26 NZ NZ579208A patent/NZ579208A/en not_active IP Right Cessation
- 2005-08-26 AU AU2005280036A patent/AU2005280036B2/en not_active Expired
- 2005-08-26 RU RU2007108717/10A patent/RU2458988C2/ru active
- 2005-08-26 PE PE2009001227A patent/PE20100448A1/es active IP Right Grant
- 2005-08-26 KR KR1020077004810A patent/KR100988451B1/ko not_active Expired - Lifetime
- 2005-08-26 EP EP05791482A patent/EP1781802B1/en not_active Revoked
- 2005-08-26 AT AT08005732T patent/ATE461285T1/de active
- 2005-08-26 CA CA2578138A patent/CA2578138C/en not_active Expired - Lifetime
- 2005-08-26 PT PT08005732T patent/PT1992697E/pt unknown
-
2007
- 2007-02-26 ZA ZA2007/01672A patent/ZA200701672B/en unknown
- 2007-02-27 EG EGNA2007000222 patent/EG26922A/xx active
- 2007-02-27 IL IL181588A patent/IL181588A/en unknown
- 2007-03-16 CR CR8998A patent/CR8998A/es unknown
- 2007-03-26 NO NO20071570A patent/NO344785B1/no not_active IP Right Cessation
- 2007-03-27 EC EC2007007354A patent/ECSP077354A/es unknown
-
2010
- 2010-01-08 CY CY20101100022T patent/CY1109721T1/el unknown
- 2010-05-14 HR HR20100271T patent/HRP20100271T1/hr unknown
- 2010-06-16 CY CY20101100556T patent/CY1110092T1/el unknown
-
2012
- 2012-02-17 JP JP2012033112A patent/JP5921910B2/ja not_active Expired - Lifetime
- 2012-11-01 CR CR20120560A patent/CR20120560A/es unknown
- 2012-11-09 AR ARP120104234A patent/AR088824A2/es not_active Application Discontinuation
-
2016
- 2016-01-28 JP JP2016014650A patent/JP2016056214A/ja active Pending
-
2017
- 2017-03-09 CL CL2017000577A patent/CL2017000577A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050537A1 (es) | Produccion de proteina de fusion tnfr-ig | |
| AR050471A1 (es) | Produccion de anticuerpos anti abeta -amiloide | |
| AR051017A1 (es) | Produccion de polipeptidos | |
| CL2008001156A1 (es) | Metodo para producir una proteina de fusion tnfr en un cultivo celular que comprende cultivar celulas de mamifero que contienen un gen que codifica la proteina de fusion en un medio de cultivo de celulas que comprende un compuesto anti-envejecimiento. | |
| MX2023004505A (es) | Polinucleotidos que contienen adn y guias para sistemas crispr de tipo v, y metodos de fabricacion y uso de los mismos. | |
| AR058140A1 (es) | Metodo de produccion proteica utilizando compuestos anti-senescencia | |
| WO2012079086A3 (en) | Mesenchymal stem cells (msc) expansion methods and materials | |
| WO2007084364A3 (en) | Improved il-12 for expression in mammalian cells | |
| AR036883A1 (es) | Limpiadores para superficies duras que contienen tensioactivos de copolimero de bloque de oxido de etileno y oxido de propileno | |
| MX2011008373A (es) | Procedimiento para la criopreservacion de celulas, construcciones celulares artificiales o ensamblajes de tejidos complejos tridimensionales. | |
| UA92157C2 (ru) | Способ продуцирования гормона роста | |
| EP4455166A3 (en) | Method for producing cd3-positive cell | |
| DE60027570D1 (de) | Verfahren zur herstellung künstlicher pflanzenchromosomen | |
| WO2016081032A3 (en) | Mesenchymal stem cells derived from induced pluripotent stem cells | |
| WO2004091033A3 (fr) | Composition reticulable pour electrolyte de batterie | |
| DK1720979T3 (da) | Anvendelse af et serumfrit celledyrkningsmedium til fremstilling af IL-18BP I pattedyrceller | |
| CO6390009A2 (es) | Reactor electrobioquimico | |
| JP2020065503A5 (es) | ||
| BRPI0814082A2 (pt) | Cultura incluindo um meio de expansão e uma composição de citocinas, método para a expansão de células-tronco, células-tronco e uso de células | |
| BRPI0418641A (pt) | organização similar a tecido de células e construtos similares a tecidos macroscópicos, gerados por cultura de macromassa de células, e método de cultura de macromassa | |
| NO20073094L (no) | Fremgangsmate for fremstilling av pattedyrceller | |
| MX2021012649A (es) | Medio de cultivo celular para celulas eucarioticas. | |
| AR112454A2 (es) | Método para la producción de polipéptidos | |
| MX2021011146A (es) | Andamio biodegradable para el crecimiento de cabello y metodos de uso para el mismo. | |
| EP3467112A3 (en) | Methods for transfecting nucleic acids into live cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |